Clinical trial: Oral drug keeps cancer treatment on track for patients who develop persistently low platelet counts
· Medical Xpressedited by Lisa Lock, reviewed by Andrew Zinin
Lisa Lock
Scientific Editor
Meet our editorial team
Behind our editorial process
Andrew Zinin
Chief Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
The GIST Add as preferred source
In a phase 2 clinical trial, Mass General Brigham Cancer Institute researchers found that the oral drug avatrombopag was safe and effective in managing persistent chemotherapy-induced thrombocytopenia (CIT) in more than half of patients with gastrointestinal cancers, offering a potential new option for managing a common and challenging complication of cancer treatment. Their work is published in the Journal of Clinical Oncology.
CIT occurs when chemotherapy lowers platelet levels, reducing the blood cells that help control bleeding. For patients receiving chemotherapy, low platelet counts are common and frequently lead to treatment delays or dose reductions. This compromises vital cancer care, potentially reducing patients' chances of cure or length of survival. However, there are currently no widely available approved therapies to address this complication.
"Chemotherapy remains a cornerstone of therapy for gastrointestinal cancers, so we want patients to be able to stay on their planned treatment," said lead and corresponding author Hanny Al-Samkari, M.D., a classical hematologist at the Mass General Brigham Cancer Institute, the Peggy S. Blitz Endowed Chair in Hematology/Oncology at Mass General Brigham, and an associate professor of medicine at Harvard Medical School. "The findings from our trial may help improve care for patients who experience persistent CIT, which has historically been a very challenging complication to manage."
Researchers enrolled 47 adults with gastrointestinal cancers and persistent CIT from four U.S. cancer centers, including Massachusetts General Hospital, and randomly assigned them to receive avatrombopag or a placebo. Participants ranged from 25 to 84 years old; 30% were women, 17% were nonwhite, and 11% were Hispanic or Latino. The study was stopped early after an independent monitoring board determined that the trial had met its prespecified stopping criteria for efficacy.
Investigators found that 70% of patients receiving avatrombopag achieved successful treatment of CIT, defined as platelet recovery and prevention of chemotherapy delays or dose reductions, compared with 17% of those receiving placebo. Platelet counts recovered in 83% of patients who received the drug, compared with 46% of those who did not. No serious adverse events were attributed to avatrombopag, and no patients required platelet transfusions.
The authors note that further research is needed to determine whether improving CIT management leads to improved long-term outcomes.
Publication details
Hanny Al-Samkari et al, Avatrombopag Versus Placebo for Persistent Chemotherapy-Induced Thrombocytopenia in GI Cancers: The Phase II ACT-GI Trial, Journal of Clinical Oncology (2026). DOI: 10.1200/jco-26-00568
Journal information: Journal of Clinical Oncology
Key medical concepts
Clinical categories
OncologyClinical pharmacology Provided by Mass General Brigham Who's behind this story?
Lisa Lock
BA art history, MA material culture. Former museum editor, paramedic, and transplant coordinator. Editing for Science X since 2021. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: Clinical trial: Oral drug keeps cancer treatment on track for patients who develop persistently low platelet counts (2026, July 20) retrieved 21 July 2026 from https://medicalxpress.com/news/2026-07-clinical-trial-oral-drug-cancer.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.